Cisplatin

Basic Information of Cisplatin

CAS No.	15663-27-1
EC No.	239-622-4
Chemical Formula	Pt(NH3)2Cl2
Molecular Weight	300.05 g/mol
Appearance	Bright yellow to yellow-orange crystalline powder
Odor	Odorless
Melting point	Decomposes >270 °C without melting
Boiling point	Not applicable (decomposes)
Density	approx. 3.70 g/cm³
Solubility	Sparingly soluble in water (~2.5 mg/mL at 25 °C); insoluble in most organic solvents
Nature (hazards)	Toxic if swallowed, causes severe skin burns and eye damage, may cause allergic skin reaction, suspected carcinogen, toxic to aquatic life with long lasting effects
RIDADR	UN 3288, Toxic solid, inorganic, n.o.s. (Cisplatin), Class 6.1, Packing Group II
Chemical Structure

Primary Applications of Cisplatin

Cisplatin remains a cornerstone chemotherapeutic agent, delivering proven clinical efficacy across multiple cancer types through its unique DNA-binding mechanism.

1. Testicular Cancer Treatment
   Serves as the standard first-line therapy for advanced testicular germ cell tumors, achieving high cure rates in combination regimens due to its exceptional sensitivity in these malignancies.

2. Ovarian Cancer Chemotherapy
   Used in frontline and recurrent platinum-sensitive ovarian cancer protocols, often in combination with taxanes or other agents, providing significant progression-free and overall survival benefits.

3. Bladder and Urothelial Cancer
   Forms the backbone of neoadjuvant, adjuvant, and metastatic cisplatin-based chemotherapy for muscle-invasive and advanced urothelial carcinoma.

4. Head and Neck Squamous Cell Carcinoma
   Essential component of concurrent chemoradiotherapy and induction regimens for locally advanced head and neck cancers, improving locoregional control and survival.

5. Lung Cancer (NSCLC)
   Included in platinum doublet regimens for advanced non-small cell lung cancer, particularly in combination with gemcitabine, pemetrexed, or vinorelbine for non-squamous histology.

6. Pharmaceutical Research & Combination Therapies
   Employed in clinical trials, liposomal formulations, nanoparticle delivery systems, and combination studies to enhance efficacy and reduce toxicity in modern oncology development.

• Pharmaceutical-Grade Purity & Compliance
  Manufactured under stringent controls with full ICH-compliant impurity profiling, stability data, and Certificates of Analysis to meet global pharmacopeial standards (USP, EP, JP).

• Precise Platinum Content Control
  Accurate Pt assay and low residual metal impurities ensure batch consistency and optimal drug product performance.

• Secure & Transparent Precious Metal Sourcing
  Responsible platinum procurement with traceability and inventory buffering to mitigate supply risks and price volatility.

• Regulatory & Technical Support
  Comprehensive DMF support, stability studies, and expert guidance on formulation, handling, and process validation for seamless integration into drug product manufacturing.

• Commitment to Oncology & Sustainability
  Dedicated to supporting life-saving therapies with ethical sourcing, platinum recycling programs, and ESG-aligned practices for responsible pharmaceutical supply.

Hazards Classification

• GHS Classification: Acute Toxicity, Oral (Category 2); Skin Corrosion (Category 1B); Serious Eye Damage (Category 1); Skin Sensitization (Category 1); Germ Cell Mutagenicity (Category 2); Carcinogenicity (Category 1B); Reproductive Toxicity (Category 1B); Specific Target Organ Toxicity, Repeated Exposure (Category 1) (kidney, bone marrow); Aquatic Chronic (Category 1)

• Hazard Statements: H300: Fatal if swallowed; H314: Causes severe skin burns and eye damage; H317: May cause an allergic skin reaction; H341: Suspected of causing genetic defects; H350: May cause cancer; H360: May damage fertility or the unborn child; H372: Causes damage to organs through prolonged or repeated exposure; H410: Very toxic to aquatic life with long lasting effects

• UN Number: UN 3288

• Hazard Class: 6.1 (Toxic substances)

• Packing Group: II